Feedback / Questions
camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics
epratuzumab-cys-tesirine (ADCT-602) - Overland ADCT BioPharma
https://www.businesswire.com/news/home/20230509005395/en/ADC-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-and-Strategy-Update
May 9, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next